BRPI1006113A2 - "derivado de piridina". - Google Patents
"derivado de piridina".Info
- Publication number
- BRPI1006113A2 BRPI1006113A2 BRPI1006113A BRPI1006113A BRPI1006113A2 BR PI1006113 A2 BRPI1006113 A2 BR PI1006113A2 BR PI1006113 A BRPI1006113 A BR PI1006113A BR PI1006113 A BRPI1006113 A BR PI1006113A BR PI1006113 A2 BRPI1006113 A2 BR PI1006113A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyridine derivative
- pyridine
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009051820 | 2009-03-05 | ||
| PCT/JP2010/053384 WO2010101164A1 (ja) | 2009-03-05 | 2010-03-03 | ピリジン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1006113A2 true BRPI1006113A2 (pt) | 2016-02-16 |
Family
ID=42709719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1006113A BRPI1006113A2 (pt) | 2009-03-05 | 2010-03-03 | "derivado de piridina". |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20120029026A1 (pt) |
| EP (1) | EP2404918B1 (pt) |
| JP (1) | JPWO2010101164A1 (pt) |
| KR (1) | KR20110123253A (pt) |
| CN (1) | CN102341386A (pt) |
| AU (1) | AU2010219705A1 (pt) |
| BR (1) | BRPI1006113A2 (pt) |
| CA (1) | CA2754446A1 (pt) |
| CO (1) | CO6362003A2 (pt) |
| ES (1) | ES2617191T3 (pt) |
| IL (1) | IL214961A0 (pt) |
| MX (1) | MX2011009244A (pt) |
| RU (1) | RU2480463C1 (pt) |
| SG (1) | SG172469A1 (pt) |
| TW (1) | TW201035074A (pt) |
| WO (1) | WO2010101164A1 (pt) |
| ZA (1) | ZA201105479B (pt) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008317353B2 (en) * | 2007-10-24 | 2014-08-07 | Merck Sharp & Dohme Llc | Heterocycle phenyl amide T-type calcium channel antagonists |
| CA2754446A1 (en) | 2009-03-05 | 2010-09-10 | Daiichi Sankyo Company, Limited | Pyridine derivative |
| US8835358B2 (en) | 2009-12-15 | 2014-09-16 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse labels |
| TW201219353A (en) * | 2010-09-07 | 2012-05-16 | Daiichi Sankyo Co Ltd | Manufacturing method of benzoates |
| CA2865575C (en) | 2012-02-27 | 2024-01-16 | Cellular Research, Inc. | Compositions and kits for molecular counting |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| KR102758333B1 (ko) | 2013-08-28 | 2025-01-23 | 벡톤 디킨슨 앤드 컴퍼니 | 대량의 동시 단일 세포 분석 |
| US9582877B2 (en) | 2013-10-07 | 2017-02-28 | Cellular Research, Inc. | Methods and systems for digitally counting features on arrays |
| DK3074400T3 (en) | 2013-11-26 | 2018-01-15 | Hoffmann La Roche | Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors |
| CA2937616A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| US10359415B2 (en) * | 2014-05-02 | 2019-07-23 | Rosemount Inc. | Single-use bioreactor sensor architecture |
| WO2016131025A1 (en) * | 2015-02-13 | 2016-08-18 | Ideation Systems Llc | Modular system including multiple detachable sensors |
| EP3259371B1 (en) | 2015-02-19 | 2020-09-02 | Becton, Dickinson and Company | High-throughput single-cell analysis combining proteomic and genomic information |
| WO2016138496A1 (en) | 2015-02-27 | 2016-09-01 | Cellular Research, Inc. | Spatially addressable molecular barcoding |
| WO2016160844A2 (en) | 2015-03-30 | 2016-10-06 | Cellular Research, Inc. | Methods and compositions for combinatorial barcoding |
| EP4582556A3 (en) | 2015-04-23 | 2025-10-08 | Becton, Dickinson and Company | Methods and compositions for whole transcriptome amplification |
| WO2016196229A1 (en) | 2015-06-01 | 2016-12-08 | Cellular Research, Inc. | Methods for rna quantification |
| CA2992889A1 (en) * | 2015-09-04 | 2017-03-09 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
| JP6940484B2 (ja) | 2015-09-11 | 2021-09-29 | セルラー リサーチ， インコーポレイテッド | ライブラリー正規化のための方法および組成物 |
| AU2016328436B2 (en) | 2015-09-24 | 2020-05-14 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| WO2017050732A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| JP6876685B2 (ja) | 2015-09-24 | 2021-05-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ａｔｘ阻害剤としての二環式化合物 |
| BR112017026682A2 (pt) | 2015-09-24 | 2018-08-14 | Hoffmann La Roche | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| JP7129343B2 (ja) | 2016-05-02 | 2022-09-01 | ベクトン・ディキンソン・アンド・カンパニー | 正確な分子バーコーディング |
| US10301677B2 (en) | 2016-05-25 | 2019-05-28 | Cellular Research, Inc. | Normalization of nucleic acid libraries |
| ES2979395T3 (es) | 2016-05-26 | 2024-09-25 | Becton Dickinson Co | Métodos de ajuste del recuento de etiquetas moleculares |
| US10202641B2 (en) | 2016-05-31 | 2019-02-12 | Cellular Research, Inc. | Error correction in amplification of samples |
| US10640763B2 (en) | 2016-05-31 | 2020-05-05 | Cellular Research, Inc. | Molecular indexing of internal sequences |
| CN109791157B (zh) | 2016-09-26 | 2022-06-07 | 贝克顿迪金森公司 | 使用具有条形码化的寡核苷酸序列的试剂测量蛋白质表达 |
| JP7228510B2 (ja) | 2016-11-08 | 2023-02-24 | ベクトン・ディキンソン・アンド・カンパニー | 細胞標識分類の方法 |
| US11164659B2 (en) | 2016-11-08 | 2021-11-02 | Becton, Dickinson And Company | Methods for expression profile classification |
| ES2961580T3 (es) | 2017-01-13 | 2024-03-12 | Cellular Res Inc | Revestimiento hidrófilo de canales de fluidos |
| CN110382708A (zh) | 2017-02-01 | 2019-10-25 | 赛卢拉研究公司 | 使用阻断性寡核苷酸进行选择性扩增 |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| CN110719959B (zh) | 2017-06-05 | 2021-08-06 | 贝克顿迪金森公司 | 针对单细胞的样品索引 |
| EP3728636B1 (en) | 2017-12-19 | 2024-09-11 | Becton, Dickinson and Company | Particles associated with oligonucleotides |
| JP7358388B2 (ja) | 2018-05-03 | 2023-10-10 | ベクトン・ディキンソン・アンド・カンパニー | 反対側の転写物末端における分子バーコーディング |
| CN112272710A (zh) | 2018-05-03 | 2021-01-26 | 贝克顿迪金森公司 | 高通量多组学样品分析 |
| ES2992135T3 (es) | 2018-10-01 | 2024-12-09 | Becton Dickinson Co | Determinar secuencias de transcripción 5 |
| US11932849B2 (en) | 2018-11-08 | 2024-03-19 | Becton, Dickinson And Company | Whole transcriptome analysis of single cells using random priming |
| CN109456259A (zh) * | 2018-11-27 | 2019-03-12 | 武汉珈瑜科技有限公司 | 酰胺类衍生物及其应用 |
| CN109293566A (zh) * | 2018-11-27 | 2019-02-01 | 武汉珈瑜科技有限公司 | 酰胺类衍生物及其应用 |
| US11492660B2 (en) | 2018-12-13 | 2022-11-08 | Becton, Dickinson And Company | Selective extension in single cell whole transcriptome analysis |
| US11371076B2 (en) | 2019-01-16 | 2022-06-28 | Becton, Dickinson And Company | Polymerase chain reaction normalization through primer titration |
| ES2945227T3 (es) | 2019-01-23 | 2023-06-29 | Becton Dickinson Co | Oligonucleótidos asociados con anticuerpos |
| WO2020167920A1 (en) | 2019-02-14 | 2020-08-20 | Cellular Research, Inc. | Hybrid targeted and whole transcriptome amplification |
| US11965208B2 (en) | 2019-04-19 | 2024-04-23 | Becton, Dickinson And Company | Methods of associating phenotypical data and single cell sequencing data |
| CN120099137A (zh) | 2019-07-22 | 2025-06-06 | 贝克顿迪金森公司 | 单细胞染色质免疫沉淀测序测定 |
| JP7522189B2 (ja) | 2019-11-08 | 2024-07-24 | ベクトン・ディキンソン・アンド・カンパニー | 免疫レパートリーシーケンシングのための完全長ｖ（ｄ）ｊ情報を得るためのランダムプライミングの使用 |
| US11649497B2 (en) | 2020-01-13 | 2023-05-16 | Becton, Dickinson And Company | Methods and compositions for quantitation of proteins and RNA |
| WO2021146219A1 (en) | 2020-01-13 | 2021-07-22 | Becton, Dickinson And Company | Cell capture using du-containing oligonucleotides |
| WO2021155057A1 (en) | 2020-01-29 | 2021-08-05 | Becton, Dickinson And Company | Barcoded wells for spatial mapping of single cells through sequencing |
| WO2021173719A1 (en) | 2020-02-25 | 2021-09-02 | Becton, Dickinson And Company | Bi-specific probes to enable the use of single-cell samples as single color compensation control |
| US11661625B2 (en) | 2020-05-14 | 2023-05-30 | Becton, Dickinson And Company | Primers for immune repertoire profiling |
| US12157913B2 (en) | 2020-06-02 | 2024-12-03 | Becton, Dickinson And Company | Oligonucleotides and beads for 5 prime gene expression assay |
| US11932901B2 (en) | 2020-07-13 | 2024-03-19 | Becton, Dickinson And Company | Target enrichment using nucleic acid probes for scRNAseq |
| US12391940B2 (en) | 2020-07-31 | 2025-08-19 | Becton, Dickinson And Company | Single cell assay for transposase-accessible chromatin |
| AU2021376300A1 (en) | 2020-11-09 | 2023-06-22 | Eisai R&D Management Co., Ltd. | ΡΡΑRγ MODULATORS AND METHODS OF USE |
| EP4247967A1 (en) | 2020-11-20 | 2023-09-27 | Becton, Dickinson and Company | Profiling of highly expressed and lowly expressed proteins |
| CN116685850A (zh) | 2020-12-15 | 2023-09-01 | 贝克顿迪金森公司 | 单细胞分泌组分析 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0842925A1 (en) | 1987-09-04 | 1998-05-20 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
| IE910278A1 (en) * | 1990-02-16 | 1991-08-28 | Ici Plc | Heterocyclic compounds |
| FR2751649B1 (fr) | 1996-07-26 | 1998-08-28 | Adir | Nouveaux derives de benzimidazole, de benzoxazole et de benzothiazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| HUP9902721A2 (hu) | 1997-11-25 | 1999-12-28 | The Procter & Gamble Co. | Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület |
| US5968960A (en) | 1999-01-14 | 1999-10-19 | The Regents Of The University Of California | Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism |
| RU2219172C2 (ru) | 1999-04-06 | 2003-12-20 | Санкио Компани, Лимитед | α-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ |
| JP4169450B2 (ja) | 1999-04-07 | 2008-10-22 | 第一三共株式会社 | インスリン抵抗性改善剤 |
| TWI284533B (en) | 1999-05-24 | 2007-08-01 | Sankyo Co | Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant |
| EP1172356B1 (en) | 2000-07-13 | 2004-10-06 | Sumitomo Chemical Company, Limited | Process for producing N-acylnitroaniline derivative |
| JP2002193948A (ja) | 2000-10-06 | 2002-07-10 | Sankyo Co Ltd | α−置換カルボン酸誘導体を含有する糖尿病治療剤 |
| DE60316780T2 (de) | 2002-02-21 | 2008-07-24 | Eli Lilly And Co., Indianapolis | Modulatoren von peroxisome proliferator-aktivierten rezeptoren |
| US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| WO2004013109A1 (ja) | 2002-08-02 | 2004-02-12 | Sankyo Company, Limited | レゾルシノール誘導体 |
| JP2004067629A (ja) * | 2002-08-09 | 2004-03-04 | Yamanouchi Pharmaceut Co Ltd | ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体 |
| US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| JP2004315404A (ja) | 2003-04-15 | 2004-11-11 | Sankyo Co Ltd | ベンゾイミダゾール誘導体を含有する医薬 |
| WO2005037763A1 (en) | 2003-10-14 | 2005-04-28 | Eli Lilly And Company | Phenoxyether derivatives as ppar modulators |
| AU2004285053B2 (en) * | 2003-10-28 | 2010-10-21 | Vertex Pharmaceuticals, Incorporated | Benzimidazoles useful as modulators of ion channels |
| SA05260265A (ar) | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| EP1798216A4 (en) | 2004-09-28 | 2008-12-03 | Sankyo Co | INTERMEDIATE PRODUCT OF A 6-SUBSTITUTED 1-METHYL-1H-BENZIMIDAZOLE DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| NZ570381A (en) | 2006-02-09 | 2011-02-25 | Daiichi Sankyo Co Ltd | Anti-cancer pharmaceutical composition |
| JP5294419B2 (ja) * | 2007-04-05 | 2013-09-18 | 第一三共株式会社 | 縮合二環式ヘテロアリール誘導体 |
| CA2754446A1 (en) | 2009-03-05 | 2010-09-10 | Daiichi Sankyo Company, Limited | Pyridine derivative |
-
2010
- 2010-03-03 CA CA2754446A patent/CA2754446A1/en not_active Abandoned
- 2010-03-03 BR BRPI1006113A patent/BRPI1006113A2/pt not_active IP Right Cessation
- 2010-03-03 MX MX2011009244A patent/MX2011009244A/es not_active Application Discontinuation
- 2010-03-03 JP JP2011502770A patent/JPWO2010101164A1/ja active Pending
- 2010-03-03 EP EP10748758.9A patent/EP2404918B1/en not_active Not-in-force
- 2010-03-03 ES ES10748758.9T patent/ES2617191T3/es active Active
- 2010-03-03 RU RU2011136681/04A patent/RU2480463C1/ru not_active IP Right Cessation
- 2010-03-03 SG SG2011050135A patent/SG172469A1/en unknown
- 2010-03-03 KR KR1020117020354A patent/KR20110123253A/ko not_active Withdrawn
- 2010-03-03 CN CN201080010000XA patent/CN102341386A/zh active Pending
- 2010-03-03 AU AU2010219705A patent/AU2010219705A1/en not_active Abandoned
- 2010-03-03 WO PCT/JP2010/053384 patent/WO2010101164A1/ja not_active Ceased
- 2010-03-04 TW TW099106233A patent/TW201035074A/zh unknown
-
2011
- 2011-04-15 US US13/088,103 patent/US20120029026A1/en not_active Abandoned
- 2011-07-25 ZA ZA2011/05479A patent/ZA201105479B/en unknown
- 2011-09-04 IL IL214961A patent/IL214961A0/en unknown
- 2011-09-22 CO CO11123958A patent/CO6362003A2/es not_active Application Discontinuation
-
2012
- 2012-10-20 US US13/656,664 patent/US8946264B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2404918B1 (en) | 2016-11-30 |
| CA2754446A1 (en) | 2010-09-10 |
| EP2404918A1 (en) | 2012-01-11 |
| RU2480463C1 (ru) | 2013-04-27 |
| RU2011136681A (ru) | 2013-03-10 |
| ES2617191T3 (es) | 2017-06-15 |
| US20120029026A1 (en) | 2012-02-02 |
| EP2404918A4 (en) | 2012-08-01 |
| CN102341386A (zh) | 2012-02-01 |
| JPWO2010101164A1 (ja) | 2012-09-10 |
| IL214961A0 (en) | 2011-11-30 |
| US20130045994A1 (en) | 2013-02-21 |
| SG172469A1 (en) | 2011-08-29 |
| KR20110123253A (ko) | 2011-11-14 |
| AU2010219705A1 (en) | 2011-07-21 |
| TW201035074A (en) | 2010-10-01 |
| WO2010101164A1 (ja) | 2010-09-10 |
| CO6362003A2 (es) | 2012-01-20 |
| US8946264B2 (en) | 2015-02-03 |
| ZA201105479B (en) | 2012-04-25 |
| MX2011009244A (es) | 2011-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1006113A2 (pt) | "derivado de piridina". | |
| FR24C1047I2 (fr) | Derive de 4-pyrimidinesulfamide | |
| BRPI0810202A2 (pt) | Derivados de piridina | |
| BRPI1011414A2 (pt) | "método." | |
| EP2226315A4 (en) | 2-aminoquinazoline DERIVATIVE | |
| EP2213673A4 (en) | Pyridone-substituted dihydropyrazolopyrimidine derivative | |
| ATE555107T1 (de) | 2-aza-bicyclo-ä2,2,1-üheptan-derivate | |
| BR112012000763A2 (pt) | derivados de piridin-4-ila | |
| BR112012012872A2 (pt) | "pirrolindinas de espiroindolinona" | |
| EP2376493A4 (en) | DIHYDROPYRIMIDOPYRIMIDINDERIVAT | |
| EP2380877A4 (en) | PYRIDINE-3-CARBONSÄUREAMIDDERIVAT | |
| BRPI0907563A2 (pt) | Derivados de 4,5-di-hidro-xazol-2-il amina | |
| EP2511268A4 (en) | oxazine | |
| UY33125A (es) | Diaza-espiro-[5,5]-undecanos | |
| BRPI0811718A2 (pt) | Derivados de 3,3-espiroindolinona | |
| ATE502012T1 (de) | 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivat | |
| EP2344471A4 (en) | 7-PIPERIDINALKYL-3,4-dihydroquinolone DERIVATIVE | |
| EP2336132A4 (en) | MORPHOLINPURINDERIVAT | |
| BRPI1008173A2 (pt) | "derivados de piridina espiroindolinona" | |
| BRPI0917446A2 (pt) | derivados de acilaminobenzamida. | |
| BRPI0906357A2 (pt) | Derivados de oxazepinopirimidona arilamida substituídos | |
| BRPI0815059A2 (pt) | Derivado de 1,3-di-hidroisoindol | |
| EP2459573A4 (en) | SUBSTITUTED 1,2-AZABORIN HETEROCYCLES | |
| BRPI0906714A2 (pt) | Derivados de oxazepinopirimidona heteroarilamida substituídos. | |
| BRPI1016192A2 (pt) | derivados de soxazol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2377 DE 26-07-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |